Revenue Breakdown
Composition ()
No data
Revenue Streams
Biontech SE (BNTX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Collaboration Revenue, accounting for 78.0% of total sales, equivalent to €32.59M. Other significant revenue streams include Biotech Business Unit - Manufacturing and Biotech Business Unit - Clinical. Understanding this composition is critical for investors evaluating how BNTX navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Biontech SE maintains a gross margin of 91.01%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1.54%, while the net margin is -1.89%. These profitability ratios, combined with a Return on Equity (ROE) of -3.04%, provide a clear picture of how effectively BNTX converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, BNTX competes directly with industry leaders such as NTRA and IQV. With a market capitalization of $26.97B, it holds a significant position in the sector. When comparing efficiency, BNTX's gross margin of 91.01% stands against NTRA's 66.67% and IQV's 25.64%. Such benchmarking helps identify whether Biontech SE is trading at a premium or discount relative to its financial performance.
